Cancer Immunotherapy Market based on by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics),Regional Outlook– Global Forecast up to 2030
Cancer immunotherapy medications are intended to enhance or augment the body's natural immune response to combat cancer. This market is research-driven, with a significant reliance on the identification of compounds capable of eliciting an immune response against diverse indications.
On the basis of product, the cancer immunotherapy market has been divided into monoclonal antibodies, immunomodulators, vaccines, and check point inhibitors. The check point inhibitors market is expected to grow at the fastest rate. The benefits provided by this medicinal medicine are responsible for the rapid expansion.
The worldwide cancer immunotherapy market is divided into several applications, including lung cancer, breast cancer, colorectal cancer, prostate cancer, multiple myeloma, melanoma, head and neck cancer, and others. The worldwide cancer immunotherapy market is expected to be dominated by lung cancer. The lung cancer category was predicted to have the highest share in the next five years as the number of people suffering from lung illnesses increased.
On the basis of product, the cancer immunotherapy market has been divided into monoclonal antibodies, immunomodulators, vaccines, and check point inhibitors. The check point inhibitors market is expected to grow at the fastest rate. The benefits provided by this medicinal medicine are responsible for the rapid expansion.
The worldwide cancer immunotherapy market is divided into several applications, including lung cancer, breast cancer, colorectal cancer, prostate cancer, multiple myeloma, melanoma, head and neck cancer, and others. The worldwide cancer immunotherapy market is expected to be dominated by lung cancer. The lung cancer category was predicted to have the highest share in the next five years as the number of people suffering from lung illnesses increased.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Monoclonal Antibodies
5.3. Cancer Vaccines
5.4. Checkpoint Inhibitors
5.5. Immunomodulators
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Lung Cancer
6.3. Breast Cancer
6.4. Head and Neck Cancer
6.5. Prostate Cancer
6.6. Colorectal Cancer
6.7. Melanoma
6.8. Others
7. END USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospitals
7.3. Clinics & Others
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AMGEN, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ASTRAZENECA, PLC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. BAYER AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BRISTOL-MYERS SQUIBB COMPANY
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. ELI LILY AND COMPANY
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.)
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. PFIZER, INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. MERCK KGAA
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. NOVARTIS AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
TABLE 1. CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 7. CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
TABLE 8. CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. CANCER IMMUNOTHERAPY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 15. CANCER IMMUNOTHERAPY MARKET VALUE FOR Hospitals, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. CANCER IMMUNOTHERAPY MARKET VALUE FOR Clinics & Others, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 21. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 24. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 25. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 27. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 28. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 30. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 31. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 34. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 35. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 36. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 37. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 38. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 40. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 41. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 43. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 44. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 46. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 49. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 50. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 56. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 57. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 59. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 60. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 61. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 62. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 63. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 67. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 70. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 76. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 79. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 82. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 83. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 84. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 88. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 89. AMGEN, INC. : FINANCIALS
TABLE 90. AMGEN, INC. : PRODUCTS & SERVICES
TABLE 91. AMGEN, INC. : RECENT DEVELOPMENTS
TABLE 92. ASTRAZENECA, PLC: FINANCIALS
TABLE 93. ASTRAZENECA, PLC: PRODUCTS & SERVICES
TABLE 94. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
TABLE 95. BAYER AG: FINANCIALS
TABLE 96. BAYER AG: PRODUCTS & SERVICES
TABLE 97. BAYER AG: RECENT DEVELOPMENTS
TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 101. ELI LILY AND COMPANY: FINANCIALS
TABLE 102. ELI LILY AND COMPANY: PRODUCTS & SERVICES
TABLE 103. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
TABLE 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
TABLE 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
TABLE 106. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
TABLE 107. PFIZER, INC. : FINANCIALS
TABLE 108. PFIZER, INC. : PRODUCTS & SERVICES
TABLE 109. PFIZER, INC. : DEVELOPMENTS
TABLE 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
TABLE 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
TABLE 112. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
TABLE 113. MERCK KGAA: FINANCIALS
TABLE 114. MERCK KGAA: PRODUCTS & SERVICES
TABLE 115. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 116. NOVARTIS AG: FINANCIALS
TABLE 117. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 118. NOVARTIS AG: RECENT DEVELOPMENTS
CHART. 1. CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 2. CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 5. CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 7. CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
CHART. 8. CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 9. CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 11. CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 12. CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 13. CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 14. CANCER IMMUNOTHERAPY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 15. CANCER IMMUNOTHERAPY MARKET VALUE FOR Hospitals, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 16. CANCER IMMUNOTHERAPY MARKET VALUE FOR Clinics & Others, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 17. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 21. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 22. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 23. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 24. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 25. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 26. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 27. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 28. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 29. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 30. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 31. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 32. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 33. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 34. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 35. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 36. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 37. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 38. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 39. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 40. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 41. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 42. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 43. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 44. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 45. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 46. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 47. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 48. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 49. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 50. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 51. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 52. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 53. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 54. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 55. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 56. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 57. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 58. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 59. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 60. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 61. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 62. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 63. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 64. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 65. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 66. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 67. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 68. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 69. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 70. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 71. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 72. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 73. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 74. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 75. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 76. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 77. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 78. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 79. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 80. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 81. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 82. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 83. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 84. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 85. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 86. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 87. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 88. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 89. AMGEN, INC. : FINANCIALS
CHART. 90. AMGEN, INC. : PRODUCTS & SERVICES
CHART. 91. AMGEN, INC. : RECENT DEVELOPMENTS
CHART. 92. ASTRAZENECA, PLC: FINANCIALS
CHART. 93. ASTRAZENECA, PLC: PRODUCTS & SERVICES
CHART. 94. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
CHART. 95. BAYER AG: FINANCIALS
CHART. 96. BAYER AG: PRODUCTS & SERVICES
CHART. 97. BAYER AG: RECENT DEVELOPMENTS
CHART. 98. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
CHART. 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
CHART. 100. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
CHART. 101. ELI LILY AND COMPANY: FINANCIALS
CHART. 102. ELI LILY AND COMPANY: PRODUCTS & SERVICES
CHART. 103. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
CHART. 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
CHART. 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
CHART. 106. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
CHART. 107. PFIZER, INC. : FINANCIALS
CHART. 108. PFIZER, INC. : PRODUCTS & SERVICES
CHART. 109. PFIZER, INC. : DEVELOPMENTS
CHART. 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
CHART. 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
CHART. 112. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
CHART. 113. MERCK KGAA: FINANCIALS
CHART. 114. MERCK KGAA: PRODUCTS & SERVICES
CHART. 115. MERCK KGAA: RECENT DEVELOPMENTS
CHART. 116. NOVARTIS AG: FINANCIALS
CHART. 117. NOVARTIS AG: PRODUCTS & SERVICES
CHART. 118. NOVARTIS AG: RECENT DEVELOPMENTS
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Monoclonal Antibodies
5.3. Cancer Vaccines
5.4. Checkpoint Inhibitors
5.5. Immunomodulators
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Lung Cancer
6.3. Breast Cancer
6.4. Head and Neck Cancer
6.5. Prostate Cancer
6.6. Colorectal Cancer
6.7. Melanoma
6.8. Others
7. END USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospitals
7.3. Clinics & Others
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America (U.S., Mexico, Canada)
8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
8.5. Latin America (Brazil, Argentina)
8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. AMGEN, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ASTRAZENECA, PLC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. BAYER AG
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. BRISTOL-MYERS SQUIBB COMPANY
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. ELI LILY AND COMPANY
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.)
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. PFIZER, INC.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC)
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. MERCK KGAA
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. NOVARTIS AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
TABLE 1. CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 7. CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
TABLE 8. CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. CANCER IMMUNOTHERAPY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 15. CANCER IMMUNOTHERAPY MARKET VALUE FOR Hospitals, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. CANCER IMMUNOTHERAPY MARKET VALUE FOR Clinics & Others, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 21. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 24. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 25. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 27. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 28. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 30. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 31. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 34. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 35. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 36. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 37. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 38. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 40. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 41. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 43. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 44. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 46. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 49. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 50. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 56. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 57. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 59. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 60. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 61. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 62. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 63. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 67. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 70. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 76. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 79. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 82. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 83. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 84. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 88. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 89. AMGEN, INC. : FINANCIALS
TABLE 90. AMGEN, INC. : PRODUCTS & SERVICES
TABLE 91. AMGEN, INC. : RECENT DEVELOPMENTS
TABLE 92. ASTRAZENECA, PLC: FINANCIALS
TABLE 93. ASTRAZENECA, PLC: PRODUCTS & SERVICES
TABLE 94. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
TABLE 95. BAYER AG: FINANCIALS
TABLE 96. BAYER AG: PRODUCTS & SERVICES
TABLE 97. BAYER AG: RECENT DEVELOPMENTS
TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 101. ELI LILY AND COMPANY: FINANCIALS
TABLE 102. ELI LILY AND COMPANY: PRODUCTS & SERVICES
TABLE 103. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
TABLE 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
TABLE 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
TABLE 106. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
TABLE 107. PFIZER, INC. : FINANCIALS
TABLE 108. PFIZER, INC. : PRODUCTS & SERVICES
TABLE 109. PFIZER, INC. : DEVELOPMENTS
TABLE 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
TABLE 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
TABLE 112. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
TABLE 113. MERCK KGAA: FINANCIALS
TABLE 114. MERCK KGAA: PRODUCTS & SERVICES
TABLE 115. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 116. NOVARTIS AG: FINANCIALS
TABLE 117. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 118. NOVARTIS AG: RECENT DEVELOPMENTS
CHART. 1. CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 2. CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
CHART. 3. CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 5. CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 7. CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
CHART. 8. CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 9. CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 11. CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 12. CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 13. CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 14. CANCER IMMUNOTHERAPY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
CHART. 15. CANCER IMMUNOTHERAPY MARKET VALUE FOR Hospitals, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 16. CANCER IMMUNOTHERAPY MARKET VALUE FOR Clinics & Others, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 17. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 21. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 22. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 23. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 24. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 25. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 26. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 27. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 28. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 29. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 30. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 31. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 32. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 33. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 34. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 35. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 36. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 37. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 38. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 39. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 40. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 41. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 42. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 43. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 44. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 45. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 46. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 47. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 48. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 49. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 50. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 51. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 52. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 53. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 54. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 55. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 56. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 57. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 58. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 59. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 60. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 61. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 62. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 63. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 64. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 65. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 66. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 67. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 68. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 69. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 70. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 71. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 72. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 73. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 74. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 75. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 76. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 77. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 78. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 79. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 80. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 81. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 82. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 83. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 84. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 85. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 86. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
CHART. 87. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
CHART. 88. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
CHART. 89. AMGEN, INC. : FINANCIALS
CHART. 90. AMGEN, INC. : PRODUCTS & SERVICES
CHART. 91. AMGEN, INC. : RECENT DEVELOPMENTS
CHART. 92. ASTRAZENECA, PLC: FINANCIALS
CHART. 93. ASTRAZENECA, PLC: PRODUCTS & SERVICES
CHART. 94. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
CHART. 95. BAYER AG: FINANCIALS
CHART. 96. BAYER AG: PRODUCTS & SERVICES
CHART. 97. BAYER AG: RECENT DEVELOPMENTS
CHART. 98. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
CHART. 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
CHART. 100. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
CHART. 101. ELI LILY AND COMPANY: FINANCIALS
CHART. 102. ELI LILY AND COMPANY: PRODUCTS & SERVICES
CHART. 103. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
CHART. 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
CHART. 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
CHART. 106. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
CHART. 107. PFIZER, INC. : FINANCIALS
CHART. 108. PFIZER, INC. : PRODUCTS & SERVICES
CHART. 109. PFIZER, INC. : DEVELOPMENTS
CHART. 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
CHART. 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
CHART. 112. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
CHART. 113. MERCK KGAA: FINANCIALS
CHART. 114. MERCK KGAA: PRODUCTS & SERVICES
CHART. 115. MERCK KGAA: RECENT DEVELOPMENTS
CHART. 116. NOVARTIS AG: FINANCIALS
CHART. 117. NOVARTIS AG: PRODUCTS & SERVICES
CHART. 118. NOVARTIS AG: RECENT DEVELOPMENTS
